Increasing survival in HCV-related hepatocellular carcinoma

The benefits of direct-acting antiviral (DAA) therapy for hepatitis C in patients with hepatocellular carcinoma (HCC) have been debated. In a retrospective cohort study of 797 patients with HCV-related HCC with a complete response to HCC treatment (383 patients received DAAs, 414 patients did not), DAA therapy was associated with a significant reduction in the risk of death (HR 0.54; 95% CI 0.33–0.90). Furthermore, this association differed by whether or not patients had achieved a sustained virologic response (SVR) to DAA therapy, with risk of death reduced in those who had achieved SVR (HR 0.29; 95% CI 0.18–0.47), but not in those who did not achieve SVR (HR 1.13; 95% CI 0.55–2.33).


Original article

  1. Singal, A. G. et al. Direct-acting antiviral therapy for HCV infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology (2019)

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Katrina Ray.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ray, K. Increasing survival in HCV-related hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 16, 582 (2019).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing